Sign up
Pharma Capital

Avacta Group signs licensing deal with New England Biolabs (NEB)

Alastair Smith, chief executive of Avacta Group Plc (LON:AVCT),  discusses with Proactive Investors a licensing deal they've signed with New England Biolabs (NEB), an enzyme discovery and production company, to commercialise its Affimer technology for use in life science research and diagnostic assays.

Smith says they've been collaborating with NEB to develop Affimers to combine with NEB’s reagents (a substance used for chemical analysis).

 

View full AVCT profile View Profile
View All

© biotech Capital 2018

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.